Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death.
Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
